To explore the adjuvant treatment of chronic glomerulonephritis(CGN) with nephritis rehabilitation tablets, and its influence on peripheral mononuclear cell B7-1, soluble FMS-like tyrosine kinase(sFlt)-1 and renal fibrosis indicators.
A total of 120 CGN patients in our hospital from January 2021 to December 2024 were selected for the study. They were randomly divided into the experimental group and the control group by simple sorting method, with 60 cases in each group. Eventually, the number dropped to 55 cases in each group and was included in the data analysis. Both groups received basic treatment. The control group was treated with cyclophosphamide, while the experimental group was supplemented with nephritis rehabilitation tablets. The clinical efficacy, B7-1, sFlt-1, renal fibrosis indicators [cystatin C(CysC), transforming growth factor(TGF)-β1, fibronectin(FN)], serum creatinine(Scr), urinary protein(UP), time for improvement of clinical symptoms (time for disappearance of nausea, vomiting, edema and fatigue), and occurrence of adverse reactions of the two groups were compared.
The total effective rate of treatment in the experimental group was higher than that in the control group(92.73% vs. 78.18%, P<0.05). After treatment, the levels of B7-1, sFlt-1, CysC, TGF-β1, Scr,, BUN, β2-MG and CD8+ in both groups decreased compared with those before treatment, and the levels in the experimental group were lower than those in the control group(P<0.05).After treatment, the FN and CD4+ in both groups increased compared with those before treatment, and the experimental group was higher than the control group(P<0.05). The improvement time of clinical symptoms in the experimental group was shorter than that in the control group(P<0.05). There was no statistically significant comparison of the incidence of adverse reactions between the two groups(P>0.05).
In patients with CGN, the administration of nephritis rehabilitation tablets as an adjunct can help reduce the expression of B7-1, down-regulate the level of sFlt-1, and improve renal fibrosis.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |